Bifogade filer
Devyser to share data at ASHI 2024 demonstrating its innovations and studies within transplantation
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Devyser’s post-transplant products will be featured in 7 posters at the upcoming American Society of Histocompatibility and Immunogenetics (ASHI) meeting at Anaheim California in October, highlighting advancements in donor-derived cell-free DNA (dd-cfDNA) monitoring and innovations. These presentations include performance assessments of novel assays and advancements in monitoring tools for kidney and lung transplants. We will present a new prototype product for the absolute quantification of dd-cfDNA using next-generation sequencing (NGS). The research underscores Devyser's commitment to driving innovation in transplantation diagnostics and improving patient care.
"Devyser is a pioneering leader within the field of transplant diagnostics. We are committed to advancing the field together with our collaborators and partners, and we are now showcasing some of our latest studies and inventions at the upcoming ASHI meeting in the USA", says CSO Michael Uhlin. "We look forward to sharing and discussing with the transplant community how our tests can contribute towards improved outcomes in post-transplant monitoring."
Complete list of Devyser and collaborator presentations at ASHI 2024
| Abstract | Title (Platinum Ballroom unless otherwise specified) | Product |
| P605 | Performance Assessment of the One Lamba Devyser Accept cfDNA assay in lung transplantation | One Lambda Devyser Accept cfDNA |
| P613 | Pooling HLA, chimerism, and cfDNA NGS libraries for sequencing on Illumina instruments | One Lambda Devyser Accept cfDNA One Lambda Devyser Chimerism |
| P703 | Advancing transplantation monitoring and disease insight | In development |
| P704 | Absolute quantification of dd-cfDNA using a novel NGS assay | In development |
| P714 | Evaluation of cfDNA extraction method | One Lambda Devyser Accept cfDNA |
| P716 | Advancements in monitoring donor-derived cell-free DNA for improved kidney re-transplantation outcomes | One Lambda Devyser Accept cfDNA |
| Session Abstract V | Comparing the performance of Devyser and CareDx NGS based-assays for monitoring donor-derived cell-free DNA in kidney allografted patients | One Lambda Devyser Accept cfDNA |
The One Lambda™ Devyser Accept cfDNA test, is for detecting donor-derived cell-free DNA in kidney transplant patients. Advyser Solid Organs is our dedicated software solutions for streamlined, user-friendly, and fast monitoring of donor-derived cell-free DNA (dd-cfDNA) in patients following kidney transplantation.
The One Lambda Devyser transplantation products are CE-IVD certified but not FDA-cleared. Availability in each country depends on local regulatory marketing authorization status. Please consult your local sales representative for details.